Infusional 5FU and Neulasta – pro
Theoretically Neulasta should not be given with chemotherapy, but most oncologists now beleive that there is only a relative contraindicaiton. The concern is that Naulsta may induce white cell production, which chemotheraphy will then ablate, resulting in higher rates of neutropenia than without Neulast. 5FU infusion has a very short half life, 10 minutes, and there is little effect on the marrow while Neulasta begins to work. Therefore, there is very little basis to be concerned aobut a negatitve interaction between infusional 5FU and Neuelasta.
M. Blaschke et al, Measurements of 5-FU Plasma Concentrations in Patients with Gastrointestinal Cancer: 5-FU Levels Reflect the 5-FU Dose Applied. Journal of Cancer Therapy, 2012, 3, 28-36
Neulasta, Precribing Information 2017